Analysis: Diclofenac's heart risks warrant caution

02/14/2013 | TheHeart.org (Montreal) (free registration)

Diclofenac, a nonsteroidal anti-inflammatory drug, was associated with an up to 63% higher risk of cardiovascular events, and should be eliminated from essential-medicines lists, according to a meta-analysis published online in PLoS Medicine. Diclofenac was the most widely used NSAID in 15 countries, and its heart risk was comparable to that of rofecoxib, which was withdrawn from the market due to its cardiovascular toxocicty.

View Full Article in:

TheHeart.org (Montreal) (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY